



msk announces closing of merger and initial nasdaq listing of variation biotechnologies

September 5, 2014

Mitchell, Silberberg & Knupp* announced that its client Variation Biotechnologies (US) Inc. ("VBI") completed a merger with Paulson Capital (Delaware), Inc. (NASDAQ: PLCC) concurrently with two private placements totaling \$16.25 million from biotech venture capital investors and other institutional investors. The post-merger entity, named VBI Vaccines Inc., is listed on the NASDAQ Capital Market under the symbol "VBIV".

The Mitchell, Silberberg & Knupp* team was led by Co-Managing Partner, Kevin Friedmann, and included Gabrielle Napolitano and Bryan Wasser. VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets.

**Handled through the predecessor law firm of Richardson Patel LLP.*

practice areas

capital markets & securities
corporate & business
transactions
mergers & acquisitions